- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01323075
Pharmacodynamic Comparison of Truncal Blocks in Patients With or Without Metabolic Disease (Kidney Failure, Diabetes)
March 25, 2015 updated by: Centre Hospitalier Universitaire de Nīmes
The primary objective is to demonstrate a longer period of neurologic recovery from a sensory block assessed in each test group versus the group without metabolic disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
120
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Montpellier Cedex 05, France, 34295
- Hôpital Lapeyronnie CHU de Montpellier
-
Quincy-sous-Sénart, France, 91480
- Hôpital Privé Claude Galien
-
-
Gard
-
Nîmes Cedex 09, Gard, France, 30029
- Centre Hospitalier Universitaire de Nîmes
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Three patient populations schelduled for surgery on the hand or wrist.
The three groups include (1) patients with no metabolic or neurologic disease history, (2) patients with renal insufficiency but not diabetes and (3) patients with diabetes but not renal insufficiency.
Description
General Inclusion Criteria:
- The patient must have given his/her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- The patient is available for 1 month of follow up
- The patient is scheduled for hand or wrist surgery
Inclusion Criteria for the "Renal Insufficiency" group
- Patient has renal insufficiency as defined by a creatine clearance of < 30ml/min without dialysis
Inclusion Criteria for the "Diabetes" group
- Patient has chronic hyperglycemia, either a fasting glycemia > 1.26 g/l (7mmol/l) for longer than 5 years and receiving an oral, well-adjusted (last HBA1c < 6.5%)), non-insulin, antidiabetic treatment
Inclusion Criteria for the "Non-exposed" group
- Patient without metabolic or neurologic disease, with creating clearance > 90ml/min
Exclusion Criteria:
- The patient is participating in another study
- The patient is in an exclusion period determined by a previous study
- The patient is under judicial protection, under tutorship or curatorship
- The patient refuses to sign the consent
- It is impossible to correctly inform the patient
- The patient is pregnant
- The patient is breastfeeding
- Patient weighs less than 50 kg
- Score ASA > 4
- contra indication for locoregional anesthesia
- Severe metabolic and / or decompensated renal disease, cardiac or pulmonary decompensation
- Associated peripheral neuropathy associated with diabetes or kidney disease
- Associated central neuropathy associated (eg MS ... narrow cervical canal)
- Patients with both renal failure and diabetes
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Renal insufficiency group
Patients in this group have renal insufficiency as defined by a creatinine clearance of < 30 ml/min without dialysis.
These patients do not have diabetes.
|
Patients will have a truncal block during hand or wrist surgery.
|
Diabetic group
These patients have diabetes, but not renal insufficiency.
|
Patients will have a truncal block during hand or wrist surgery.
|
Non-exposed group
These patients have neither a neurological nor a metabolic disease and a creatine clearance of > 90 ml/min
|
Patients will have a truncal block during hand or wrist surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The duration of sensory block in minutes.
Time Frame: Day 0 (per-op)
|
The duration of the sensory block in minutes.
The beginning of this term is defined by the end of the axillary block (last injection), and the end of this period is defined by the reappearance of sensitivity to touch in the area anesthetized.
|
Day 0 (per-op)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time necessary for completion of axillary blocks (1 / 3 upper humerus)(min)
Time Frame: Day 0 (per-op)
|
Day 0 (per-op)
|
|
Time necessary for installing sensory and motor block (min)
Time Frame: Day 0 (per-op)
|
Time necessary for installing sensory and motor block (min): defined by the delay between the end of the block injection and the occurrence of insensitivity of blocked territories
|
Day 0 (per-op)
|
Failure of the block: yes / no
Time Frame: Day 0 (per-op)
|
Failure of the block: yes / no: defined by an absence of sensory block
|
Day 0 (per-op)
|
Presence of paresthesia: yes / no
Time Frame: Day 0 (per-op)
|
Day 0 (per-op)
|
|
Occurrence of neurological complications, yes/no
Time Frame: Day 0 (post-op)
|
Neurological: occurrence of complications (paresthesia, paralysis, paresis ....) that persist (or not) until the final postoperative evaluation
|
Day 0 (post-op)
|
Occurrence of neurological complications, yes/no
Time Frame: 1 month
|
Occurrence of neurological complications (paresthesia, paralysis, paresis ....)
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Philippe Cuvillon, MD, Centre Hospitalier Universitaire de Nîmes
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (Actual)
July 1, 2013
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
March 24, 2011
First Submitted That Met QC Criteria
March 24, 2011
First Posted (Estimate)
March 25, 2011
Study Record Updates
Last Update Posted (Estimate)
March 26, 2015
Last Update Submitted That Met QC Criteria
March 25, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LOCAL/2010/PC-02
- 2010-024519-15 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
Clinical Trials on Truncal block
-
Baylor Research InstituteNot yet recruiting
-
University of RochesterUniversity of California, San Francisco; EndoVx, Inc.CompletedMorbid ObesityUnited States
-
Central Carolina Surgery, PAEndoVx, Inc.TerminatedHypertension | Diabetes | Urinary Incontinence | Obstructive Sleep Apnea | Hypercholesterolemia | Morbid Obesity | Hypertriglyceridemia
-
Icahn School of Medicine at Mount SinaiCompletedPostoperative Pain | Intraoperative PainUnited States
-
ElsanCompletedAnesthesia, Local | Carpal Tunnel | Median Nerve NeuralgiaFrance
-
National Cancer Institute, EgyptRecruiting
-
University of FloridaUnited States Department of Defense; Brooks RehabilitationRecruiting
-
Huazhong University of Science and TechnologyRecruitingPain, Acute | Nerve Block | Thoracic AnesthesiaChina
-
Kyungpook National University HospitalCompletedPain | Radicular; Neuropathic, Cervical
-
University of PennsylvaniaAbiomed Inc.Not yet recruiting